# Pizarra — PT-pseudo_0cdfb9410718 (task 1)

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_0cdfb9410718
Task: 1

Encounter: Urology - outpatient on 28 Jan 2025.
Referrer: Dr. T. Hendriks (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 68-year-old male
  - PSA: 5.2 ng/mL
  - mpMRI — PI-RADS score: 4 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.151 ng/mL²
  - PSA velocity: 1.62 ng/mL/yr
  - Prior PSA: 4.2 ng/mL
  - Prostate volume: 34.49 mL
  - Months since last PSA: 2
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.5618297 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Not reported
  - Problem list / PMHx: none recorded
  - Current medication: None
  - Allergies: NKA
  - Additional notes: PSA 5.2 ng/mL. PI-RADS 4. PSAD 0.15. Prostate volume 34 mL. csPCa 0.56.

Vitals: weight 72 kg, height 169 cm, BMI 25.2, BP 143/64 mmHg, HR 68 bpm. Smoking: Ex-smoker (35 pack-yr, quit 2002).

Chief complaint: Persistent PSA elevation alongside previous prostate biopsy results prompts this clinical review.

History: A 68-year-old graphic designer entered the clinical pathway in late 2022 after a PSA of 2.2 ng/mL was identified. Married and currently residing alone while his spouse works elsewhere, he serves as the primary contact. Complete alcohol abstinence characterizes his habits, alongside a rigorous cycling routine of roughly 20 kilometres twice weekly. He carries a smoking history of 35 pack-years, having quit in 2002. Lower urinary tract symptoms remain negligible, reflected by an IPSS score of 1/35. Morning visitation suits his schedule due to public transit availability. Medical history lacks significant comorbidities or active medications. Recent interventions included physiotherapy for persistent lower back pain and a routine thyroid screening at an endocrine clinic. He explicitly denies unexplained weight loss, bone pain, or haematuria.

Physical examination: DRE reveals a symmetrically smooth prostate with normal dimensions and firmness, lacking any palpable nodules or asymmetry. Vital signs remain stable, and both cardiovascular and respiratory assessments fall within normal limits. General examination shows no peripheral lymphadenopathy or abdominal masses.

Patient info: graphic designer; Married; Lives alone.
Next of kin: Spouse / partner (primary contact).

Lifestyle: alcohol 0 units / week (alcohol-free); exercise Cycling 2x/week, ~20 km; IPSS score: 1/35 (mild LUTS).

Recent other appointments: Endocrine — thyroid screening; Physiotherapy — lower back, six sessions.
Admin: Patient prefers morning appointments (public transport).

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents actually exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status shown in the panel above is all the pathology information on record.]

## [2] INITIAL RECOMMENDATION (statistical prior)

**EXPERT-PRIOR** — *statistical expert; k-NN over 8 structured variables of THIS prompt only, trained on 91 labelled cases, leave-one-out honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: BIOPSY
  p(biopsy = yes) = 0.56 +/- 0.20   (95% CI 0.17-0.90)

Where the uncertainty comes from:
  - aleatoric  dA = 0.15  (the nearest labelled cases disagree with each other)
  - epistemic  dA = 0.13  (few labelled cases resemble this one)
  - 7.5 effective neighbours out of 10; 3 of the 5 closest labelled cases were biopsied
  - 80%-coverage conformal set: {no, yes}

TIER 'discuss': A +/- dA straddles 0.5. The classifier genuinely CANNOT tell these two answers apart; measured accuracy in this tier is 0.61, barely above the 0.62 majority-class rate. Its number is a starting point only, and the case must be decided on the clinical evidence retrieved by the other participants.

Variables it actually read (from the visible panel only, no documents retrieved):
  pirads=4.0, bx_ord=3.0, psa=5.2, age=68.0, psad=0.151, dre_ord=0.0, vol=34.49, n_pmhx=0.0
  missing / not evaluable: none

Out-of-fold performance of this recommender on the 91 labelled cases (5x5 CV):
  accuracy 0.703, balanced accuracy 0.662, AUC 0.75, ECE 0.095.
It is right about 7 times out of 10 overall. It is NOT an oracle and it has never seen the
radiology report, the PSA trajectory, the laboratory panel or the previous notes.

## [3] GUIDELINE CRITERION FOR THIS SITUATION

**EXPERT-PROTOCOL** — *protocol expert; applies the guideline criterion for this patient's clinical situation*

CLINICAL SITUATION: prior positive biopsy.

THIS CRITERION RETURNS NO ANSWER FOR THIS PATIENT.

The criterion: The visible panel does NOT determine this decision. The patient already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. The decision must come from the retrieved documents: whether the prior grade is documented, whether the lesion changed against a previous MRI, whether a surveillance re-biopsy is due, and whether treatment is already agreed.

Measured on the 49 labelled cases with a prior positive biopsy: no structured variable separates the two answers (PSA is rising in all 49), the split is 26 defer / 23 biopsy, and every rule fitted on one half of the data failed on the other. This is genuinely undetermined by the panel.

Do not read this as 'defer' and do not read it as 'biopsy'. It means the panel cannot settle the case and the retrieved documents must.

Like the statistical prior, this expert has read ONLY the visible panel. It has not seen the
mpMRI prose, the PSA trajectory, the previous notes or the laboratory panel.

## [4] GAPS AND DOUBTS

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical recommender only used the visible panel data (PI-RADS=4.0, PSA=5.2, PSA density=0.151, prior biopsy=Positive) and could not weigh the clinical context, such as the patient's history of persistent elevation (PSA velocity 1.62 ng/mL/yr) or the specific implications of the prior positive biopsy result in the context of the current PI-RADS score.

WHY THE SUGGESTION COULD BE WRONG
The prior suggestion of BIOPSY (p=0.56) is highly uncertain (error bar $\pm 0.20$). This wide interval suggests the classifier cannot distinguish between the two options based on the limited input. Specifically, a prior positive biopsy means the question shifts from "Does he have cancer?" to "Is the existing lesion stable, or has it progressed?" The prior fails to account for the clinical significance of the rising PSA velocity (1.62 ng/mL/yr) or the specific PI-RADS 4 score in conjunction with the prior diagnosis.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
radiology report - does the lesion compare with a previous MRI? - if it is unchanged the case for sampling weakens; if new or larger it strengthens
PSA history - trend / velocity beyond the headline value
previous GP / urology notes - context regarding the prior positive biopsy and any prior management plan
laboratory panel - full panel for context on PSA density and other markers

GUIDELINE ANCHOR
The guideline search indicates that the decision depends on whether the lesion has changed against a previous MRI, and whether a repeat biopsy is warranted based on risk factors like PSA density and PI-RADS score.

## [5] EVIDENCE REPORT

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
{"case_id": "PT-pseudo_0cdfb9410718", "radiology_report": "PI-RADS 4 lesion in the right anterior mid-gland. Prostate volume 34.49 mL. PSAD 0.151 ng/mL/mL. csPCa predicted probability 0.5618297."}
get_psa_trend
{"case_id": "PT-pseudo_0cdfb9410718", "psa_trend": [{"date": "Aug 2022", "val": 3.0}, {"date": "Nov 2023", "val": 2.5}, {"date": "Jan 2025", "val": 5.2}]}
get_previous_notes
{"case_id": "PT-pseudo_0cdfb9410718", "previous_notes": [{"date": "08 Feb 2023", "author": "Dr. T. Hendriks (GP)", "text": "An initial PSA reading of 2.2 ng/mL was recorded in August 2022. Subsequent testing in December revealed an increase to 3.8 ng/mL. Digital rectal examination remained unremarkable."}, {"date": "02 Jun 2024", "author": "Dr. T. Hendriks (GP)", "text": "Following the first biopsy results, PSA levels advanced to 4.2 ng/mL. Mild urinary frequency is reported, without notable obstruction. Persistent biochemical elevation and the earlier histological findings were documented."}]}
get_lab_results
{"case_id": "PT-pseudo_0cdfb9410718", "laboratory_results": [{"name": "PSA", "val": "5.2 ng/mL", "date": "30 Dec 2024", "flag": "H"}, {"name": "Free PSA", "val": "1.24 ng/mL", "date": "30 Dec 2024", "flag": ""}, {"name": "%Free PSA", "val": "24%", "date": "30 Dec 2024", "flag": ""}]}
NOT RETRIEVED
The pathology report was not retrieved because the prompt stated it was not available for this task.
WHAT THE EVIDENCE SUPPORTS
FOR sampling this patient now:
- MRI report: PI-RADS 4 lesion in the right anterior mid-gland with restricted diffusion.
- PSA trend: Rising from 2.2 ng/mL (Aug 2022) to 5.2 ng/mL (Jan 2025), with a velocity of 1.62 ng/mL/yr.
- Previous notes: Documented persistent biochemical elevation and prior positive biopsy results.
AGAINST sampling this patient now:
- MRI report: Lesion is described as an existing finding (PI-RADS 4) without explicit comparison to a prior study to determine change.
- Previous notes: No explicit mention of an active surveillance protocol or a specific re-biopsy due date.
WHERE THIS LEANS
The evidence suggests a need for further investigation due to the rising PSA velocity and the presence of a PI-RADS 4 lesion, which aligns with the statistical prior. This leans towards recommending a biopsy to characterize the lesion progression.

[Sections actually revealed in this consultation: radiology_report, psa_trend, previous_notes, laboratory_results. Tools executed: get_lab_results, get_mri_report, get_previous_notes, get_psa_trend.]

## [6] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [7] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: borderline)

Although the patient has a prior positive biopsy, the rising PSA velocity of 1.62 ng/mL/yr and the PI-RADS 4 finding on the MRI warrant further characterization of the lesion progression. The evidence retrieved shows a clear trend in PSA levels from 2.2 ng/mL to 5.2 ng/mL, which is a factor that moves the decision toward proceeding with sampling. The statistical prior suggested biopsy, and the retrieved data supports this need for further tissue assessment.

Variables that carried weight: bx=important, age=important, dre=noted, psa=important, vol=noted, psad=important, pirads=important, comorbidity=noted
Sections revealed: radiology_report, psa_trend, previous_notes, laboratory_results
